IVF-Focused Mobile Platform 'QuYun' Secures RMB 60 Million Series A Funding from BlueRun Ventures

On February 18, 2016, “Quyun” APP (Jiahao Technology), a one-stop preconception care service platform targeting individuals facing fertility challenges, announced that it had completed its Series A financing round of RMB 60 million, with BlueRun Ventures as the investor.

“QuYun” (formerly known as “Ask a Doctor”) is a one-stop preconception care service platform designed and developed by Jiahao Technology for individuals facing difficulties in conceiving and bearing children. Established in March 2014, Jiahao Technology is an internet company specializing in mobile healthcare. It secured RMB 5 million in angel investment in April 2014 and RMB 30 million in Pre-A round funding from Huaze Capital in April 2015. The QuYun app is currently available on both iOS and Android mobile operating systems; users can search for “QuYun” to download and use it.

According to the latest "Report on the Current Status of Infertility in China," jointly released by the China Population Association and the National Health and Family Planning Commission, the prevalence of infertility in China is approximately 12.5%–15%, affecting over 40 million individuals. This means that one in every eight couples faces infertility issues. As maternal age increases, fertility declines; a woman’s fertility at age 40 is half that of a woman at age 35. Consequently, many such couples need to rely on assisted reproductive technology (ART) to conceive.

“QuYun” Team Introduction: The first test-tube baby in mainland China was born in 1988 and is now in their twenties, intelligent and healthy. In terms of the overall birth rate via in vitro fertilization (IVF), the United States stands at approximately 1.5%, Northern Europe at around 5%, and Shanghai also approaches 1%.

QuYun has found that most users are unsure how to select the appropriate hospital and treatment plan when undergoing in vitro fertilization (IVF), which, to some extent, results in a “low” IVF success rate.

In fact, due to individual differences, users should select doctors and treatment plans based on their actual physical conditions (data), rather than blindly opting for experts or professors.

This is precisely the origin of QuYun: to establish a one-stop preconception care service platform that improves the success rate of assisted reproductive technology through doctor-patient interactions, peer support among patients, patient self-service, and big data analytics.

It is reported that QuYun was co-founded by a team comprising Harvard-educated medical doctors who returned to China, renowned reproductive medicine specialists and PhDs from leading domestic and international reproductive medicine centers, as well as an internet product, technology, and data team with prior experience at Microsoft, Baidu, 360, Tencent, and Alibaba. The team possesses extensive practical expertise in assisted reproduction, healthcare product development and operations, and big data processing. In February 2016, QuYun was honored as the “Best Startup” at the Annual Internet Healthcare Awards hosted by VCBeat.

Zhu Tianyu, Partner at BlueRun Ventures, stated that QuYun excels at identifying pain points in the patient experience during diagnosis and treatment. By leveraging a mature patient management platform, it provides valuable analytical insights and clinical recommendations to both patients and physicians, significantly enhancing the diagnostic and therapeutic experience through online and offline channels, thereby benefiting patients. Furthermore, QuYun has the opportunity to extend its optimization expertise to related niche markets. Entrepreneurial teams that combine product-oriented thinking with robust capabilities in medical products or services are a key focus of BlueRun’s healthcare investments.

Huaze Capital strongly endorses QuYun’s business logic and strategic direction, viewing its investment in QuYun as a low-risk endeavor with significant social value. Although Huaze is a newly established RMB-denominated fund, its team possesses robust capabilities in capital operations and internet resource integration, which will undoubtedly generate strong synergies with QuYun’s development.

In this transaction, Duan & Duan Law Firm provided legal services on behalf of Jiahao Technology, while Han Kun Law Offices represented BlueRun Ventures.

Jiahao Technology (Quyun):Jiahao Technology (Co-founder’s WeChat: jiahao-me), established in March 2014, is an internet company specializing in mobile healthcare. It secured RMB 5 million in angel investment in April 2014 and RMB 30 million in Pre-A round funding from Huaze Capital in April 2015. Jiahao Technology has designed and developed “Quyun” APP, a one-stop preconception care service platform tailored for individuals facing fertility challenges. The app is currently available on both iOS and Android platforms; users can search for “Quyun” to download and use it.

BlueRun Ventures:BlueRun Ventures is one of the earliest global early-stage venture capital funds to invest in China’s mobile internet healthcare sector, serving as an early investor in star projects such as Chunyu Doctor, Xingshulin, Meisheng Gene, and Dajia Zhongyi.

BlueRun China, established in 2005, makes investments ranging from $100,000 to $10 million. Its portfolio spans sectors such as internet finance, healthcare, online education, enterprise services/big data, and consumer lifestyle. BlueRun China was the lead Series A investor in numerous prominent companies, including Ganji.com, Meilishuo, Changba, Chunyu Doctor, QingCloud, Xiaojin Wealth Management, Joymeng.com, Qufenqi, TaoDangpu, Geek Academy, Starry Piano School, Echo, and PPTV.

BlueRun Ventures (Lanchi Venture Capital), established in 1998, manages over $1 billion in funds and served as the lead investor for prominent companies such as PayPal, Waze, Kabbage, and Banjo. As a global venture capital firm, BlueRun Ventures maintains offices in Silicon Valley, Beijing, Shanghai, and Seoul.

Huaze Capital: Huaze Capital is an investment firm specializing in early-stage investments and providing financial advisory services to enterprises. As a leading venture capital firm in China, it aims to help early-stage startups launch and grow rapidly.

Huaze Capital’s funds are sourced from top-tier domestic institutions and investors, including professional institutional investors and renowned angel investors. Huaze Capital invests in China’s most elite entrepreneurial talent. The entrepreneurs partnered with Huaze Capital include outstanding executives who have held senior management positions at large corporations, as well as highly accomplished serial entrepreneurs with multiple successful exits. Their deep expertise and extensive experience in their respective fields contribute significantly to the robust development of their companies.

Huaze Capital focuses on TMT, consumer services, cultural media and other fields, adheres to value investment, focuses on growth premium, helps the growth of local excellent enterprises, provides financial support for enterprise development, and provides multi-faceted value-added services in enterprise management, development strategy, capital operation and other aspects.